Every accountable care model eventually runs into the same wall, and it is not clinical — it is arithmetic. The benchmark.
How CMS sets the spending target an ACO is measured against has quietly determined the fate of more value-based programs than any care model ever did. LEAD’s most important bet is an attempt to escape that trap. Whether it works is the question worth watching.
- The ratchet effect, plainly
In most prior models, the reward for lowering cost was a harder target next time.
When benchmarks are rebased against an ACO’s own recent performance, success is self-defeating: cut spending this cycle, and your future benchmark resets downward to match. The better you perform, the less room you have to keep performing.
High-performing ACOs rarely fail because they stop improving. They fail because the math stops rewarding it.
- What went wrong in REACH
This is not theoretical. CMS’s own preview evaluation of ACO REACH showed rising net spending despite positive gross savings, prompting financial-methodology changes for performance year 2026 to shore up sustainability.
When a model produces clinical savings but loses money on net, the benchmark and discount mechanics are usually the reason. REACH’s four-year horizon also meant organizations were always operating near a reset.
- LEAD’s bet: no rebasing for ten years
LEAD eliminates benchmark rebasing for its full ten-year period and pairs it with a redesigned benchmarking approach meant to balance historical and regional spending.
The logic: give organizations a long, stable target so multi-year investments in care management can actually pay back before the goalposts move. For anyone who has watched a promising ACO get rebased into futility, the appeal is obvious.
- The unanswered questions
A ten-year benchmark only helps if the starting line is fair.
CMS has not fully released how LEAD will weight historical versus regional spending, how it will trend benchmarks, or how it will keep efficient ACOs from being penalized for already being efficient — the kind of benchmarking problems that have dogged accountable care for years.
No rebasing is powerful, but only if the initial benchmark and the trend are set right. The press release cannot tell you that; the methodology papers will.
- What to do with the uncertainty
You do not get to wait for perfect clarity. Practically: model your organization against a range of benchmark scenarios rather than a single assumption; watch the trend and discount mechanics as closely as the headline risk percentages; and remember that a stable benchmark rewards real, durable cost reduction — not one-time coding gains, which a tighter audit environment is increasingly likely to claw back.
The organizations that win under LEAD will be the ones that actually changed care, because the benchmark design is built to reward exactly that and little else.
Final Thoughts
The flashy parts of a value-based model are the risk tracks and the care innovations. The part that decides who survives is the benchmark.
LEAD’s no-rebasing bet is the most serious attempt yet to stop punishing the organizations that succeed, and as someone who has spent years where strategy meets the financial and regulatory detail, I’d argue it is the feature to watch above all others. Read the methodology, not the brochure. That is where the next decade of your economics is written.
If you’re evaluating LEAD, the risk track will get the attention, but the benchmark will decide your economics. At HealtheNomics, we help organizations stress-test LEAD’s benchmarking against their own spending history — so the participation decision rests on math, not marketing.
Explore the services: https://healthenomics.com/services-2/
Request a strategy conversation: https://healthenomics.com/contact-us/
Connect on LinkedIn: https://www.linkedin.com/in/muhammad-ayoub-ashraf/
Website: https://www.drayoubashraf.com
Watch on YouTube: https://www.youtube.com/@HealtheNomics
